Dr. Clay Siegell: Seattle Genetics Co-Founder, President, CEO And Chairman

Visit the WordPress page of groundbreaking biotechnology specialist Dr. Clay Siegall, the co-founder and CEO of Seattle Genetics, a leading cancer care facility, and it reveals his diverse interests and love of sports. With the Super Bowl a hot topic of conversation, Dr. Siegall’s WordPress page features tons of football related stories. They include ‘The Swami’ Chris Burman’s pick to win Super Bowl LII, how the Eagles are scouting Super Bowl referee Gene Steratore and his crew as they get ready for the Super Bowl and Patriot’s tight end Rob Gronkowski clearing the concussion protocol.

Outside of football, Dr. Siegall’s WordPress page reveals an interest in a number of other topics. They include: The flu on college campuses and the Gesundheit Machine, President Trump’s Nuclear Report mentioning a Russian ‘Doomsday Weapon’, a story about women in science called ‘Leaky Pipelines’: Plug The Holes Or Change The System?, From Scraps To Snacks, a story about turning juice bar left-overs into new food products, California apparently headed for another drought and the Wikipedia picture of the day: A marmot sitting atop Mount Dana in Yosemite, California. This man of science obviously has diverse interests.

Dr. Clay Siegall is a University of Maryland graduate with a BS in zoology. He also earned a Ph.D. in Genetics at George Washington University. Prior to co-founding Seattle Genetics in 1998, Dr. Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institutes of Health as well as the National Cancer Institute. He also holds 15 patents, is a widely published author and is on the board of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical and Washington Roundtable.

As a scientist, Dr. Siegall’s training focused on targeted cancer therapies. As chairman, president and CEO of Seattle Genetics, he’s involved in capital-raising activities that have reached out to public and private sources and secured $1.2 billion in financing. Dr. Siegall has also secured FDA approval for ADCETRIS, the company’s first ADC product and worked with Takeda Pharmaceutical Company to market it in 65 countries. Ernst & Young voted Dr. Clay Siegall Pacific Northwest Entrepreneur of the Year in 2012.